These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 28539218)

  • 1. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 4. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic activity.
    Okazaki S; Noguchi-Yachide T; Sakai T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2016 Nov; 24(21):5258-5269. PubMed ID: 27591006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
    Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
    Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
    Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
    J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
    dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
    J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors.
    Grether U; Benz J; Hartung T; Roth D
    Methods Mol Biol; 2023; 2576():145-153. PubMed ID: 36152183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation.
    Suhara W; Koide H; Okuzawa T; Hayashi D; Hashimoto T; Kojo H
    J Dairy Sci; 2009 Sep; 92(9):4180-7. PubMed ID: 19700678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.